33 results

• Dupixent Cutaneous T-Cell Lymphoma Warning Label Update Being Evaluated by FDA

  September 15, 2025

  Russell Maas

  Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.

• Dupixent T-Cell Lymphoma Lawsuits May Follow Recent Studies Linking Drug to Cancer Risks

  September 4, 2025

  Russell Maas

  Dupixent lawsuits are now being investigated after studies and FDA reports link Dupixent (dupilumab) to cutaneous T-cell lymphoma (CTCL).

• Dupixent Side Effects May Increase Cutaneous T-Cell Lymphoma (CTCL) Risks

  August 26, 2025

  Irvin Jackson

  Recent studies warn that the eczema treatment Dupixent appears to significantly increase the risk of cutaneous T-cell lymphoma (CTCL).